1. Intravenous etidronate in the management of malignant hypercalcaemia;Ryzen, E.; Martodam, R.R.; Troxell, M.;Arch Intern Med
2. Hypercalcaemia of malignancy: treatment with intravenous dichloromethylene diphosphonate;Jacobs, T.P.; Siris, E.S.; Bilezekian, J.P.; Baguiran, D.C.; Shane, E.; Canfield, R.E.;Arch Intern Med
3. Comparison of intravenous (3-amino-l-hydroxypropylidene) 1,1 bisphosphonate and volume repletion in cancer associated hypercalcaemia;Sleeboom, H.P.; Bijvoet, O.L.M.; van Oosteroom, A.T.; Gleed, J.T.; O'Riordan, J.L.H.;Lancet,1983
4. Sclerosis of lytic metastases after aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma;Morton, A.R.; Cantrill, J.A.; Pillai, G.V.; McMahon, A.; Anderson, D.C.; Howell, A.;Br Med J
5. hydroxypropyledine bisphosphonate (APD) for the treatment of bone metastases from breast cancer;Coleman, R.E.; Woll, P.J.; Miles, M.; Rubens, R.;Br J Cancer,1,